Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
United Therapeutics Corporation - Common Stock
(NQ:
UTHR
)
546.94
+14.16 (+2.66%)
Delayed Quote
Updated: 12:16 PM EDT, Oct 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about United Therapeutics Corporation - Common Stock
< Previous
1
2
3
4
5
Next >
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
September 30, 2026
From
United Therapeutics
Via
Business Wire
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
September 08, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
September 02, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
September 01, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
August 28, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
August 24, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
August 17, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
August 05, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
July 29, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
July 23, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
July 22, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Acquires Thymmune Therapeutics
July 02, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
June 29, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
May 27, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026
May 18, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
May 17, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial
May 15, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
May 12, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
May 11, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Reports First Quarter 2026 Financial Results
May 06, 2026
From
United Therapeutics Corporation
Via
Business Wire
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
May 06, 2026
From
MannKind
Via
GlobeNewswire
United Therapeutics Corporation Announces Retirement of Professor Raymond Dwek, C.B.E., F.R.S., From Its Board of Directors
April 29, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Report First Quarter 2026 Financial Results Before Market Open on Wednesday, May 6, 2026
April 22, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Presents New Data Spanning Pulmonary Hypertension Treatment, Lung Donor Expansion, and Xenotransplantation at ISHLT 2026
April 20, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for miroliverELAP® for Treatment of Acute Liver Failure
April 08, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
March 30, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Full Results of TETON-2 Phase 3 Clinical Trial Published in The New England Journal of Medicine
March 11, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces $2 Billion Stock Repurchase Authorization and Enters into $1.5 Billion Accelerated Share Repurchase Program
March 09, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation to Present at the Leerink Global Healthcare Conference
March 03, 2026
From
United Therapeutics Corporation
Via
Business Wire
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy
March 02, 2026
From
United Therapeutics Corporation
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
